Evidence map›Paper›PMID 31119693›Full record

ArticleAdvances in therapy2019

YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome.

Xin Du, Yang Zheng, Ping Yang, Shuren Ma, Zaixin Yu, Xi Su, Junbo Ge, Maria Leonsson-Zachrisson, Xianhong Wang, Jing Sun and 3 more

Registry-linked trialOpen access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02430493 (A Multi-Centre, Prospective Cohort, Non-Interventional Study About Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02430493 completednot on this map

A Multi-Centre, Prospective Cohort, Non-Interventional Study About Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients

Typeobservational_patient_registrySponsorAstraZenecaRan2015 to 2017Enrolled1,066ConditionsAcute Coronary Syndrome (ACS)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Xin DuBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yang ZhengThe First Hospital of Jilin University, Changchun, Jilin, China.
Ping YangChina-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Shuren MaHuai'an First People's Hospital, Huai'an, Jiangsu, China.
Zaixin YuXiangya Hospital, Central South University, Changsha, Hunan, China.
Xi SuWuhan Asia Heart Hospital, Wuhan, Hubei, China.
Junbo GeZhongshan Hospital, Fudan University, Shanghai, China.
Maria Leonsson-ZachrissonGlobal Medicines Development, AstraZeneca R&D Gothenburg, Mölndal, Gothenburg, Sweden.
Xianhong WangMedical Affairs, AstraZeneca China, Shanghai, China.
Jing SunMedical Affairs, AstraZeneca China, Shanghai, China.
Lu BaiMedical Affairs, AstraZeneca China, Shanghai, China.
Chang-Sheng MaBeijing Anzhen Hospital, Capital Medical University, Beijing, China. chshma@vip.sina.com.
YINGLONG study investigators
Capital Medical University · CNShanghai Medical Information Center · CNCentral South University · CNJilin University · CNSun Yat-sen University · CNBeijing Anzhen Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTicagrelor is an oral, reversible, direct-acting P2Y

methodsYINGLONG, a single-arm, phase-IV, 1-year, non-interventional study, described the safety of ticagrelor 90 mg twice daily in Chinese patients (≥ 18 years) with ACS treated with ≥ 1 dose of ticagrelor. Primary outcomes were the incidence of adverse events (AEs), in particular, PLATelet inhibition and patient Outcomes (PLATO)-defined bleeding AEs, and other serious AEs during the 1-year follow-up. Key secondary outcomes were the incidence of major cardiovascular events.

resultsPatients (n = 1041, median age 61.0 years) had started ticagrelor and had post-dose data. Median duration of ticagrelor treatment was 357 days; 577 patients (55.4%) completed 1-year ticagrelor treatment; 973 patients (93.5%) completed 1-year follow-up. Overall, 38.7% of patients reported an AE during treatment. The most common AEs were dyspnea (n = 37, 3.6%), petechiae (n = 30, 2.9%), and chest discomfort (n = 28, 2.7%). Serious AEs, excluding bleeding, were reported in 9.8% of patients during treatment. Incidence of PLATO-defined major bleeding events was 1.1% (n = 11). Of the 21 deaths that occurred during the study (8 post-treatment), 1 was a fatal bleed. Major cardiovascular events were reported in 37 patients (3.6%).

conclusionsTicagrelor was well tolerated with a low rate of PLATO-defined major bleeding events in Chinese ACS patients. Safety results were consistent with the known ticagrelor profile.

trial registrationClinicalTrials.gov identifier, NCT02430493.

fundingAstraZeneca Investment (China) Co., Ltd.

Indexed as

HemorrhageTicagrelorAcute Coronary SyndromeChinaCohort StudiesFemaleHumansMaleMiddle AgedPlatelet Aggregation InhibitorsProspective StudiesRisk FactorsTreatment OutcomePlatelet Aggregation InhibitorsTicagrelorAcute coronary syndromeBleedingCardiologyChinese patientsSafetyTicagrelor

Identifiers

PMID31119693
PMCPMC6822841
OpenAlexW2946018563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.